BioPharmSignal logoBioPharmSignal

Biotech News

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MacroGenics (MGNX)MacroGenicsCompany update

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc.

Open original release

Related news

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MGNXMacroGenics2026-05-14 20:01 EST

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

ERASErasca2026-05-11 11:00 EST

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

KURAKura Oncology2026-05-06 11:30 EST

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

View all latest news

MacroGenics

MacroGenics is an oncology company focused on engineered antibodies and targeted cancer therapies. The company has long been known for antibody engineering and immuno-oncology programs.

Recent company news

MGNXMacroGenics2026-05-14 20:01 EST

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MGNXMacroGenics2026-05-11 21:20 EST

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-05-04 11:30 EST

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MGNXMacroGenics2026-04-08 20:30 EST

FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study

Stock data

Close
4.00 USD
Market cap
257.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States